CTOs on the Move

Verinetics

www.verinetics.com

 
Verinetics is a company that provides the DispenSecur solution for Opioid Medication Management, which offers better control for controlled substances and integrates into existing pharmacy and patient management practices.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Surgical Theater

Seamlessly integrating patient-specific surgical planning and navigation, professional education and rehearsal experiences with incredible VR-empowered patient engagement capabilities

WN Pharmaceuticals

WN Pharmaceuticals Ltd is a Coquitlam, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accupac Inc

Accupac has proven to be a leader in the contract manufacturing of a variety of medical devices. Our syringe technology is just one example. We have the capability to manufacture the product, fill, label and then seal the syringe into a thermoform tray

illumiPure

illumiPure’s patented Air Guardian and CleanWhite product solutions provide continuous and powerful disinfection to safely eradicate surface and air pathogens, as well as viruses, including SARS-CoV-2, the virus that causes COVID-19, while continuously...

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.